Rising production costs and the prolonged delay in reviewing the prices of drugs covered under the National Health Insurance Scheme (NHIS) are threatening to push pharmaceutical manufacturers to the wall, the leading industry body has told the B&FT.
As a result of the weakness of the cedi, manufacturers have to contend with high prices of imported raw materials. Meanwhile, the prices of medications covered under the NHIS, which are supposed to be reviewed every six months, have seen no change in two years. �Due to the inaction of the NHIA (National Health Insurance Authority), the increasing cost of production brought about by the depreciation of the cedi and the high cost of importing raw materials, manufacturers are now hard-pressed.
We have written to the Authority but they are yet to respond,� Kwabena Asante, General Secretary of the Pharmaceutical Manufacturers Association of Ghana (PMAG), said in an Interview.
�It doesn�t look like the Authority is going to review it any time soon,� he added.
<<Print>>